Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: Correlation with histology

Tumor Biology

Volumn 30, Issue 3, 2009, Pages 121-129

  Molina, Rafael ^a   Augé, Josep M ^a   Bosch, Xavier ^a   Escudero, José M ^a   Viñolas, Nuria ^a   Marrades, Ramón ^a   Ramírez, José ^a   Carcereny, Enric ^a   Filella, Xavier ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

CA 125; CEA; CYFRA 21 1; Histological diagnosis; Lung cancer; NSE; ProGRP; SCC; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADENOCARCINOMA; ADULT; AGED; ALGORITHM; ARTICLE; BLOOD LEVEL; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

EID: 66449111135     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000224628     Document Type: Article

References (40)

1. Spira A; Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.
2. Stupp R, Monnerat C, Turrisi AT, Perry MC, Leyvraz S: Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004;45:105-117. (Pubitemid 38757838)
3. Schiller JH: Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001;61:3-13. (Pubitemid 33757971)
4. Stieber P, Dienemann H, Hasholzner U, Zimmermann A, Hofmann K, Fateh-Moghadam A: Tumour associated antigens in the differential diagnosis of lung tumours of unknown origin. Anticancer Res 1995;15:2389-2393.
5. Molina R, Filella X, Augé JM, Fuentes R, Bover I, Rifa J, et al: Tumour markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003;24:209-218.
6. Nisman B, Heching N, Barak V: Serum tumor markers in resectable and non-resectable non-small cell lung cancer. J Tumor Marker Oncology 2000;15:195-207.
7. Scheulen ME, Klanig H, Wiefelspÿtz JK, et al: Pre-therapeutic evaluation of cytokeratin fragment 19 (CYFRA 21-1) in 240 patients with lung cancer in comparison to CEA, NSE, SCC-Ag, TPA and TPS. Tumor Diagn Ther 1997;18:14-19.
8. Molina R, Agusti C, Mañe M, Filella X, Jo J, Gimenez N, et al: CYFRA 21.1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Int J Biol Markers 1994;9:96-101. (Pubitemid 24225520)
9. Plebani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A: Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer 1995;72:170-173.
10. Niklinski J, Furman M, Laudanski J, Kozlowski M: Prognostic value of pretreatment CEA, SCC-Ag and CA 19-9 levels in sera of patients with non-small cell lung cancer. Eur J Cancer Prev 1992;1:401-406.
11. Foa P, Fornier M, Miceli R: Tumor markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res 1999;19:3613-3618. (Pubitemid 30000228)
12. Diez M, Torres A, Maestro ML, Ortega D, Gomez A, Pollan M, et al: Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA 125 and SCC antigens in resectable non-small cell lung cancer. Br J Cancer 1996;73:1248-1254. (Pubitemid 26162341)
13. Viñolas N, Molina R, Galan MC, Casas F, Callejas MA, Filella X, et al: Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report. Anticancer Res 1998;18:631-634. (Pubitemid 28174884)
14. Paone G, De Angelis G, Munno R: Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA 21-1. Eur Respir J 1995;8:1136-1140.
15. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L: Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002;48:1931-1937. (Pubitemid 35222751)
16. Reinmuth N, Bradt B, Semik M, Kunze WP, Achatzy R, Scheld HH, et al: Prognostic impact of CYFRA 21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002;36:265-270. (Pubitemid 34497125)
17. Niho S, Nishiwaki Y, Goto K, Ohmatsu H, Matsumoto T, Hojo F, et al: Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer 2000;27:159-167. (Pubitemid 30105655)
18. Shibayama T, Ueoka H, Nishi K, Kiura K, Tabata M, Miyatake Y, et al: Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small cell lung cancer (SCLC). Lung Cancer 2001;32:61-69.
19. Jorgensen LG, Osterlind K, Genolla J, et al: Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer 1996;74:463-467. (Pubitemid 26254580)
20. Molina R, Filella X, Auge JM: ProGRP: A new biomarker for small cell lung cancer. Clin Biochem 2004;37:505-511. (Pubitemid 38845013)
21. Stieber P, Dinemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, et al: Pro-gastrin-releasing Peptide (ProGRP) - a useful marker in small cell lung carcinomas. Anticancer Res 1999;19:2673-2678. (Pubitemid 29392436)
22. Lamy PJ, Grenier J, Kramar A, Pujol JL: Progastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. Lung Cancer 2000;29:197-203.
23. Goto K, Kodoma T, Hojo F, Kubota K, Kahinuma R, Matsumoto T, et al: Clinicopathologic characteristics of patients with non-small cell lung carcinoma with elevated serum progastrin-releasing peptide levels. Cancer 1998;82:1056-1061. (Pubitemid 28136517)
24. Aoyagi K, Miyake Y, Urakami K, Kashiwakuma T, Hasegawa A, Kodoma T, et al: Enzyme immunoassay of immunoreactive progastrin-releasing peptide (31-98) as tumor marker for small cell lung carcinoma: development and evaluation. Clin Chem 1995;41:537-543.
25. Molina R, Alicarte J, Auge JM, Filella X, Viñolas N, Ballesta AM: Pro-gastrin releasing peptide (ProGRP) in patients with benign and malignant diseases. Tumor Biol 2004;25:56-61. (Pubitemid 38822772)
26. Stieber P, Yamaguchi K: ProGRP enables diagnosis of small-cell lung cancer; in Diamandis P, Fritsche HA, Lilja H, Cham DW, Schwartz M (eds): Tumor Markers. Physiology, Pathobiology, Technology and Clinical Applications. Washington, AACC Press, 2002, pp 517-521.
27. Mountain CF: The international system for staging lung cancer. Semin Surg Oncol 2000;18:106-115. (Pubitemid 30090451)
28. Stahel RA, Ginsberg R, Haveman K,Hirsch FR, Idhe DC, Jassem J, et al: Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989;5:119-126. (Pubitemid 20053516)
29. Travis WP, Colby TV, Corrin B, Shimosato Y, Bracambilla E: Histological Typing of Lung and Pleural Tumors. World Health Organization. Berlin, Springer-Verlag, 1999.
30. Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, et al: Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 1991;37:1379-1383. (Pubitemid 21925975)
31. Molina R, Filella X, Torres MD, Ballesta AM, Mengual P, Cases A, et al: Evaluation of a new tumor marker, SCC in benign and neoplasic diseases. Clin Chem 1990;36:251-254.
32. Molina R, Agustí C, Filella X, Jo J, Joseph J, Giménez N, et al: Study of a new tumor marker, CYFRA 21-1 in malignant and nonmalignant diseases. Tumor Biol 1994;15:318-321.
33. Lassen U, Osterlind K, Hansen M, Dombernovsky P, Bergman B, Hansen HH: Long-term survival in small-cell lung cancer: post treatment characteristics in patients surviving 5 to 18+ years. An analysis of 1,714 consecutive patients. J Clin Oncol 1995;13:1215-1220.
34. Maestu I, Pastor M, Gomez Codina J: Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices in 341 patients. Ann Oncol 1997;8:547-553. (Pubitemid 27359417)
35. Okusaka T, Eguchi K, Kasai T: Serum levels of Pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res 1997;3:123-127. (Pubitemid 27079454)
36. Sunaga N, Tsuchiya S, Minato K: Serum progastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology 1999;6:143-148. (Pubitemid 29385493)
37. Takada M, Kusunoki Y, Masuda N, Matui K, Yana T, Ushijima S et al: Pro-gastrin-releasing peptide(31-98) as a tumor marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. Br J Cancer 1996;73:1227-1232.
38. Buccheri G, Torchio P, Ferrigno D: Clinical equivalence of two cytokeratin markers in non-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments. Chest 2003;124:622-632. (Pubitemid 37000143)
39. Buccheri G, Ferrigno D: Lung tumor markers in oncology practice: a study of TPA and CA 125. Br J Cancer 2002;87:1112-1118. (Pubitemid 35418106)
40. Hatzakis KD, Froudarakis ME, Bouros D, Tzanakis N, Karkavitsas N, Siafakas NM: Prognostic value of serum tumor markers in patients with lung cancer. Respiration 2002;69:25-29. (Pubitemid 34158384)